Literature DB >> 28488972

Clinically relevant non-major bleeding with oral anticoagulants: non-major may not be trivial.

Laura Franco1, Cecilia Becattini1, Simone Vanni2, Rodolfo Sbrojavacca3, Cinzia Nitti4, Giorgia Manina5, Luca Masotti6, Fulvio Pomero7, Sergio Cattinelli8, Roberto Cappelli9, Roberta Re10, Giancarlo Agnelli1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28488972      PMCID： PMC6034768          DOI： 10.2450/2017.0335-16

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  20 in total

1.  Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.

Authors:  Harry R Büller; Hervé Décousus; Michael A Grosso; Michele Mercuri; Saskia Middeldorp; Martin H Prins; Gary E Raskob; Sebastian M Schellong; Lee Schwocho; Annelise Segers; Minggao Shi; Peter Verhamme; Phil Wells
Journal:  N Engl J Med       Date:  2013-08-31       Impact factor: 91.245

2.  Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry.

Authors:  Jan Beyer-Westendorf; Kati Förster; Sven Pannach; Franziska Ebertz; Vera Gelbricht; Christoph Thieme; Franziska Michalski; Christina Köhler; Sebastian Werth; Kurtulus Sahin; Luise Tittl; Ulrike Hänsel; Norbert Weiss
Journal:  Blood       Date:  2014-05-23       Impact factor: 22.113

3.  Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Results from the AMPLIFY trial.

Authors:  Suzanne M Bleker; Alexander T Cohen; Harry R Büller; Giancarlo Agnelli; Alexander S Gallus; Gary E Raskob; Jeffrey I Weitz; Madelyn Curto; Melanie Sisson; Saskia Middeldorp
Journal:  Thromb Haemost       Date:  2016-09-01       Impact factor: 5.249

4.  All-cause and bleeding-related health care costs in warfarin-treated patients with atrial fibrillation.

Authors:  Sameer R Ghate; Joseph Biskupiak; Xiangyang Ye; Winghan J Kwong; Diana I Brixner
Journal:  J Manag Care Pharm       Date:  2011-11

Review 5.  Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis.

Authors:  T van der Hulle; J Kooiman; P L den Exter; O M Dekkers; F A Klok; M V Huisman
Journal:  J Thromb Haemost       Date:  2014       Impact factor: 5.824

6.  Oral rivaroxaban for symptomatic venous thromboembolism.

Authors:  Rupert Bauersachs; Scott D Berkowitz; Benjamin Brenner; Harry R Buller; Hervé Decousus; Alex S Gallus; Anthonie W Lensing; Frank Misselwitz; Martin H Prins; Gary E Raskob; Annelise Segers; Peter Verhamme; Phil Wells; Giancarlo Agnelli; Henri Bounameaux; Alexander Cohen; Bruce L Davidson; Franco Piovella; Sebastian Schellong
Journal:  N Engl J Med       Date:  2010-12-03       Impact factor: 91.245

7.  Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy.

Authors:  G Palareti; N Leali; S Coccheri; M Poggi; C Manotti; A D'Angelo; V Pengo; N Erba; M Moia; N Ciavarella; G Devoto; M Berrettini; S Musolesi
Journal:  Lancet       Date:  1996-08-17       Impact factor: 79.321

8.  Dabigatran versus warfarin in the treatment of acute venous thromboembolism.

Authors:  Sam Schulman; Clive Kearon; Ajay K Kakkar; Patrick Mismetti; Sebastian Schellong; Henry Eriksson; David Baanstra; Janet Schnee; Samuel Z Goldhaber
Journal:  N Engl J Med       Date:  2009-12-10       Impact factor: 91.245

9.  Hospitalization for vitamin-K-antagonist-related bleeding: treatment patterns and outcome.

Authors:  K Halbritter; J Beyer-Westendorf; J Nowotny; S Pannach; E Kuhlisch; S M Schellong
Journal:  J Thromb Haemost       Date:  2013-04       Impact factor: 5.824

10.  Edoxaban versus warfarin in patients with atrial fibrillation.

Authors:  Robert P Giugliano; Christian T Ruff; Eugene Braunwald; Sabina A Murphy; Stephen D Wiviott; Jonathan L Halperin; Albert L Waldo; Michael D Ezekowitz; Jeffrey I Weitz; Jindřich Špinar; Witold Ruzyllo; Mikhail Ruda; Yukihiro Koretsune; Joshua Betcher; Minggao Shi; Laura T Grip; Shirali P Patel; Indravadan Patel; James J Hanyok; Michele Mercuri; Elliott M Antman
Journal:  N Engl J Med       Date:  2013-11-19       Impact factor: 91.245
View more
  3 in total

1.  Serial use of existing clinical decisions aids can reduce computed tomography pulmonary angiography for pulmonary embolism.

Authors:  Robert Russell Ehrman; Adrienne Nicole Malik; Reid Kenneth Smith; Zeid Kalarikkal; Andrew Huang; Ryan Michael King; Rubin David Green; Brian James O'Neil; Robert Leigh Sherwin
Journal:  Intern Emerg Med       Date:  2021-03-20       Impact factor: 3.397

Review 2.  A Review of the Incidence Diagnosis and Treatment of Spontaneous Hemorrhage in Patients Treated with Direct Oral Anticoagulants.

Authors:  Kulothungan Gunasekaran; Venkat Rajasurya; Joe Devasahayam; Mandeep Singh Rahi; Arul Chandran; Kalaimani Elango; Goutham Talari
Journal:  J Clin Med       Date:  2020-09-15       Impact factor: 4.241

3.  Impact of pharmacist-conducted anticoagulation patient education and telephone follow-up on transitions of care: a randomized controlled trial.

Authors:  Lamis R Karaoui; Elsy Ramia; Hanine Mansour; Nisrine Haddad; Nibal Chamoun
Journal:  BMC Health Serv Res       Date:  2021-02-16       Impact factor: 2.655
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.